IMPACTO DEL COVID-19 EN PACIENTES COM CÁNCER: REVISIÓN DE ALCANCE

Silva, Tâmara Taynah Medeiros da; Araújo, Naryllenne Maciel de; Sarmento, Sabrina Daiane Gurgel; Castro, Grayce Louyse Tinoco de; Dantas, Daniele Vieira; Dantas, Rodrigo Assis Neves

doi:10.1590/1980-265X-TCE-2020-0415

person Tâmara Taynah Medeiros da Silva

schoolLiga Norte Riograndense Contra o Câncer. Natal, Rio Grande do Norte, Brasil.

person Naryllenne Maciel de Araújo

schoolUniversidade Federal do Rio Grande do Norte, Programa de Pós-Graduação em Enfermagem. Natal, Rio Grande do Norte, Brasil.

0000-0003-4776-9282

person Sabrina Daiane Gurgel Sarmento

schoolUniversidade Federal do Rio Grande do Norte, Programa de Pós-Graduação em Enfermagem. Natal, Rio Grande do Norte, Brasil.

0000-0002-5999-0139

person Grayce Louyse Tinoco de Castro

schoolLiga Norte Riograndense Contra o Câncer. Natal, Rio Grande do Norte, Brasil.schoolServiço de Atendimento Móvel de Urgência. Natal, Rio Grande do Norte, Brasil.

0000-0002-0396-8557

person Daniele Vieira Dantas

schoolUniversidade Federal do Rio Grande do Norte, Programa de Pós-Graduação em Enfermagem. Natal, Rio Grande do Norte, Brasil.

0000-0003-0307-2424

person Rodrigo Assis Neves Dantas

schoolUniversidade Federal do Rio Grande do Norte, Programa de Pós-Graduação em Enfermagem. Natal, Rio Grande do Norte, Brasil.

0000-0002-9309-2092

personCORRESPONDING AUTHOR Rodrigo Assis Neves Dantas
emailrodrigoenf@yahoo.com.br

groupsCONTRIBUTION OF AUTHORITY

Study design: Silva TTM, Araújo NM, Sarmento SDG, Castro GL, Dantas DV, Dantas RAN. Coleta de dados: Silva TTM, Araújo NM, Sarmento SDG, Castro GL, Dantas DV, Dantas RAN. Data analysis and interpretation: Silva TTM, Araújo NM, Sarmento SDG, Castro GL, Dantas DV, Dantas RAN. Discussion of results: Silva TTM, Araújo NM, Sarmento SDG, Castro GL, Dantas DV, Dantas RAN. Critical writing and/or content review: Silva TTM, Araújo NM, Sarmento SDG, Castro GL, Dantas DV, Dantas RAN. Review and approval of the final version: Silva TTM, Araújo NM, Sarmento SDG, Castro GL, Dantas DV, Dantas RAN.

CONFLICTS OF INTEREST

There is no conflict of interest.

EDITORS

Associate Editors: Gisele Cristina Manfrini, Mara Ambrosina de Oliveira Vargas, Ana Izabel Jatobá de Souza. Editor-in-chief: Roberta Costa.

PCC	MESH/DeCS		Keywords
Population	Medical Oncology/Oncologia	OR	Oncological patients
	AND
Concept	Signs and symptoms/Sinais e Sintomas
	OR
	Therapeutics/Terapêutica
	OR
	Prognosis/Prognóstico
	AND
Context	Coronavirus/Coronavírus
	OR
	Pandemics/Pandemias	OR	COVID-19

Data source	Syntax adopted
Web of Science	TS: (Medical Oncology OR Oncological patients) AND TS: (Signs and symptoms OR Therapeutics OR Prognosis) AND TS: (Coronavirus OR COVID-19 OR Pandemics)
LILACS*	Medical Oncology [Words] OR Oncological patients [Words] AND Signs and symptoms [Words] OR Therapeutics [Words] OR Prognosis [Words] AND Coronavirus [Words] OR COVID-19 [Words] or Pandemics [Words]
Scopus†	(TITLE-ABS-KEY (Medical Oncology OR Oncological patients) AND TITLE-ABS-KEY (Signs and symptoms OR Therapeutics OR Prognosis)) AND (TITLE-ABS-KEY (Coronavirus OR COVID-19 OR Pandemics))
MEDLINE‡	(“Medical Oncology” [All Fields] OR “Oncological patients” [All Fields]) AND (“Signs and symptoms” [All Fields] OR “Therapeutics” [All Fields] OR “Prognosis” [All Fields]) AND (“Coronavirus” [All Fields] OR “COVID-19” [All Fields] OR “Pandemics” [All Fields])
CINAHL§	(Medical Oncology OR Oncological patients) AND (Signs and symptoms OR Therapeutics OR Prognosis) AND (Coronavirus OR COVID-19 OR Pandemics)
Science Direct	(SU (Medical Oncology OR Oncological patients)) AND (SU (Signs and symptoms OR Therapeutics OR Prognosis)) AND (SU (Coronavirus OR COVID-19 OR Pandemics))
SciELO\|\|	(*”Medical Oncology” OR “Oncological patients”) AND (“Signs and symptoms” OR “Therapeutics” OR “Prognosis”) AND (“Coronavirus” OR “COVID-19” OR “Pandemics”)
Cochrane Library	(Medical Oncology OR (Oncological patients)) AND (Signs and symptoms OR (Therapeutics OR (Prognosis)) AND (Coronavirus OR (COVID-19) OR (Pandemics))
Wiley¶	(“Medical Oncology” OR “Oncological patients”) AND (“Signs and symptoms” OR “Therapeutics” OR “Prognosis”) AND (“Coronavirus” OR “COVID-19” OR “Pandemics”)
Catalog of Theses and Dissertations (CAPES)	(“Medical Oncology” OR “Oncological patients”) AND (“Signs and symptoms” OR “Therapeutics” OR “Prognosis”) AND (“Coronavirus” OR “COVID-19” OR “Pandemics”)
Google Scholar	(“Medical Oncology” OR “Oncological patients”) AND (“Signs and symptoms” OR “Therapeutics” OR “Prognosis”) AND (“Coronavirus” OR “COVID-19” OR “Pandemics”)

ID	Title	Country Year	Data source	Study sample	Level of evidence/Degree of recommendation
A1	High mortality rate in patients with cancer with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR¹³	France 2020	Web of Science	302	Cohort study 2B/B
A2	Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak¹⁴	China 2020	Web of Science	105	Cohort study 2B/B
A3	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study¹⁵	Italy 2020	Web of Science	200	Cohort study 2B/B
A4	COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study¹⁶	United Kingdom 2020	Web of Science	800	Cohort study 2B/B
A5	Case Fatality Rate of Patients with cancer with COVID-19 in a New York Hospital System¹⁷	USA* 2020	Web of Science	218	Cohort study 2B/B
A6	Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study¹⁸	China 2020	Web of Science	232	Cohort study 2B/B
A7	Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study¹⁹	China 2020	Web of Science	205	Cohort study 2B/B
A8	SARS-CoV-2 infection in patients with cancer undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death²⁰	Spain 2020	Web of Science	63	Cohort study 2B/B
A9	Clinical characteristics of COVID-19-infected patients with cancer: a retrospective case study in three hospitals within Wuhan, China ²¹	China 2020	Web of Science	28	Cohort study 2B/B
A10	COVID-19 in persons with haematological cancers²²	China 2020	MEDLINE†	13	Cohort study 2B/B
A11	Mortalidad por covid-19 en pacientes con cáncer en un hospital de Madrid durante las primeras 3 semanas de epidemic ²³	Spain 2020	Science Direct	15	Retrospective 3A/B
A12	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study²⁴	USA* 2020	Science Direct	928	Cohort study 2B/B
A13	COVID-19 in patients with lung cancer²⁵	USA* 2020	Science Direct	102	Retrospective 3A/B
A14	Determinants of COVID-19 disease severity in patients with cancer²⁶	USA* 2020	Science Direct	423	Cohort study 2B/B
A15	Covid-19 and lung cancer: A greater fatality rate ²⁷	Spain 2020	Science Direct	17	Cohort study 2B/B
A16	Outcomes of Novel Coronavirus Disease 2019 (COVID-19) Infection in 107 Patients with Cancer from Wuhan, China²⁸	China 2020	Wiley Online Library	107	Retrospective 3A/B
A17	Clinical characteristics and outcomes of patients with cancer with COVID-19²⁹	China 2020	Wiley Online Library	52	Retrospective 3A/B
A18	Characteristics and outcome of SARS-CoV-2 infection in patients with cancer³⁰	China 2020	Google Chrome Scholar	141	Cohort study 2B/B
A19	Infection rate and clinical management of patients with cancer during the COVID-19 pandemic: experience from a tertiary care hospital in northern Italy³¹	Italy 2020	Google Chrome Scholar	81	Retrospective 3A/B
A20	Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: A single-center retrospective observational study in Tokyo, Japan³²	Japan 2020	Google Chrome Scholar	32	Cohort study 2B/B
A21	Presenting Features and Early Mortality from SARS-CoV-2 Infection in Patients with cancer during the Initial Stage of the COVID-19 Pandemic in EuropA3³	Italy Spain 2020	Google Chrome Scholar	204	Cohort study 2B/B
A22	Covid-19 transmission, outcome and associated risk factors in patients with cancer at the first month of the pandemic in a Spanish hospital in Madrid³⁴	Spain 2020	Google Chrome Scholar	45	Cohort study 2B/B
A23	Coronavirus disease-2019 in patients with cancer. A report of the first 25 patients with cancer in a western country (Italy)³⁵	Italy 2020	Google Chrome Scholar	25	Cohort study 2B/B
A24	Systematic investigations of COVID-19 in 283 patients with cancer³⁶	China 2020	Google Chrome Scholar	283	Retrospective 3A/B
A25	A Multicenter Study of Coronavirus Disease 2019 Outcomes of Patients with cancer in Wuhan, China³⁷	China 2020	Google Chrome Scholar	67	Retrospective 3A/B

Type of cancer	ID of articles	N (%)
Lung	A1¹³, A2¹⁴, A3¹⁵, A4¹⁶, A5¹⁷, A7¹⁹, A8²⁰, A9²¹, A11²³, A12²⁴, A13²⁵, A14²⁶, A15²⁷, A16²⁸, A17²⁹, A18³⁰, A19³¹, A20³², A21³³, A22³⁴, A23³⁵, A24³⁶, A25³⁷	23 (92)
Hematologic	A1¹³, A2¹⁴, A4¹⁶, A5¹⁷, A7¹⁹, A10²², A11²³, A12²⁴, A14²⁶, A18³⁰, A20³², A21³³, A23³⁵, A24³⁶	14 (56)
Breast	A2¹⁴, A4¹⁶, A5¹⁷, A7¹⁹, A8²⁰, A9²¹, A12²⁴, A14²⁶, A17²⁹, A18³⁰, A19³¹, A21³³, A22³⁴, A24³⁶	14 (56)
Gastrointestinal	A2¹⁴, A4¹⁶, A7¹⁹, A8²⁰, A12²⁴, A16²⁸, A17²⁹, A18³⁰, A20³², A21³³, A23³⁴, A24³⁶	12 (48)
Colorectal	A5¹⁷, A7¹⁹, A8²⁰, A11²³, A14²⁶, A17²⁹, A19³¹, A20³², A22³⁴, A24³⁶	10 (40)
Genitourinary	A4¹⁶, A5¹⁷, A11²³, A16²⁸, A17²⁹, A18³⁰, A21³³, A23³⁵	8 (32)
Head and neck	A5¹⁷, A7¹⁹, A8²⁰, A9²¹, A16²⁸, A17²⁹, A18³⁰, A21³³	8 (32)
Prostate	A8²⁰, A9²¹ A11²³, A12²⁴, A14²⁶, A17²⁹, A20³², A22³⁴	8 (32)
Thyroid	A2¹⁴, A7¹⁹, A24³⁶	3 (12)
Comorbidities
SH*	A1¹³, A2¹⁴, A3¹⁵, A4¹⁶, A5¹⁷, A6¹⁸, A7¹⁹, A8²⁰, A9²¹, A10²², A11²³, A13²⁵, A14²⁶, A15²⁷, A16²⁸, A17²⁹, A18³⁰, A19³¹, A20³², A21³³, A22³⁴, A23³⁵, A243⁶, A25³⁷	24 (96)
DM†	A1¹³, A2¹⁴, A3¹⁵, A4¹⁶, A5¹⁷, A6¹⁸, A7¹⁹, A8²⁰, A9²¹, A11²³, A13²⁵, A14²⁶, A15²⁷, A16²⁸, A17²⁹, A18³⁰, A19³¹, A20³², A21³³, A22³⁴, A23³⁵, A243⁶, A25³⁷	23 (92)
COPD‡	A1¹³, A3¹⁵, A4¹⁶, A5¹⁷, A6¹⁸, A7¹⁹, A8²⁰, A9²¹, A11²³, A13²⁵, A14²⁶, A15²⁷, A16²⁸, A17²⁹, A18³⁰, A20³², A21³³, A22³⁴, A23³⁵, A243⁶	20 (80)
Heart disease	A2¹⁴, A3¹⁵, A4¹⁶, A6¹⁸, A7¹⁹, A8²⁰, A13²⁵, A14²⁶, A16²⁸, A17²⁹, A18³⁰, A20³², A22³⁴, A243⁶, A25³⁷	15 (60)
CKD§	A2¹⁴, A31⁵, A5¹⁷, A6¹⁸, A7¹⁹, A8²⁰, A11²³, A14²⁶, A15²⁷, A17²⁹, A19³¹, A21³³, A22³⁴, A243⁶	14 (56)
Smoking	A1¹³, A2¹⁴, A3¹⁵, A6¹⁸, A18³⁰, A19³¹, A21³³, A23³⁵	8 (32)
Obesity	A11²³, A12²⁴, A13²⁵, A15²⁷, A19³¹	5 (20)
Clinical manifestations
Fever	A1¹³, A2¹⁴, A3¹⁵, A4¹⁶, A6¹⁸, A7¹⁹, A8²⁰, A9²¹, A10²², A11²³, A12²⁴, A13²⁵, A14²⁶, A15²⁷, A16²⁸, A17²⁹, A18³⁰, A19³¹, A21³³, A22³⁴, A23³⁵, A24³⁶, A25³⁷	23 (92)
Cough	A1¹³, A2¹⁴, A3¹⁵, A4¹⁶, A6¹⁸, A8²⁰, A9²¹, A10²², A11²³, A12²⁴, A13²⁵, A14²⁶, A15²⁷, A16²⁸, A17²⁹, A18³⁰, A21³³, A22³⁴, A23³⁵, A24³⁶, A25³⁷	21 (84)
Dyspnea	A1¹³, A3¹⁵, A4¹⁶ A6¹⁸, A7¹⁹, A8²⁰, A9²¹, A10²², A11²³, A12²⁴, A13²⁵, A14²⁶, A15²⁷, A16²⁸, A18³⁰, A21³³, A22³⁴, A24³⁶, A25³⁷	19 (76)
Diarrhea	A1¹³, A3¹⁵, A4¹⁶ A6¹⁸, A7¹⁹, A8²⁰, A10²², A11²³, A13²⁵, A14²⁶, A15²⁷, A16²⁸, A17²⁹, A18³⁰, A21³³, A22³⁴, A25³⁷	17 (68)
Fatigue	A2¹⁴, A3¹⁵, A7¹⁹, A8²⁰, A9²¹, A12²⁴, A16²⁸, A17²⁹, A21³³, A24³⁶, A25³⁷	11 (44)
Myalgia	A2¹⁴, A3¹⁵, A10²², A11²³, A15²⁷, A16²⁸, A17²⁹, A21³³, A22³⁴, A25³⁷	10 (40)
Nausea and vomiting	A2¹⁴, A4¹⁶, A6¹⁸, A7¹⁹, A13²⁵, A21³³, A25³⁷	7 (28)
Headache	A2¹⁴, A3¹⁵, A6¹⁸, A10²², A17²⁹, A18³⁰, A21³³	7 (28)
Anosmia and ageusia	A1¹³, A3¹⁵, A4¹⁶, A18³⁰, A21³³	5 (20)
Treatment
Antivirals	A2¹⁴, A6¹⁸, A7¹⁹, A8²⁰, A9²¹, A10²², A11²³, A15²⁷, A16²⁸, A17²⁹, A18³⁰, A21³³, A22³⁴, A23³⁵, A24³⁶, A25³⁷	16 (64)
Antibiotics	A2¹⁴, A6¹⁸, A7¹⁹, A8²⁰, A9²¹, A10²², A11²³, A12²⁴, A15²⁷, A16²⁸, A17²⁹, A18³⁰, A21³³, A22³⁴, A24³⁶	15 (60)
IMV \|\|	A3¹⁵, A5¹⁷, A6¹⁶, A7¹⁸, A9²¹, A10²², A12²⁴, A13²⁵, A14²⁶, A16²⁸, A21³³, A24³⁶, A25³⁷	13 (52)
Oxygen therapy	A2¹⁴, A4¹⁶, A6¹⁸, A7¹⁹, A9²¹, A10²², A13²⁵, A14²⁶, A17²⁹, A21³³, A23³⁵, A25³⁷	12 (48)
Non-Invasive	A2¹⁴, A3¹⁵, A7¹⁹, A9²¹, A10²², A17²⁹, A18³⁰, A21³³, A22³⁴, A25³⁷	10 (40)
Glucocorticoids	A8²⁰, A11²³, A12²⁴, A13²⁵, A15²⁷, A16²⁸, A21³³, A22³⁴, A23³⁵	9 (36)
Chloroquines	A6¹⁸, A7¹⁹, A16²⁸, A17²⁹, A25³⁷	5 (20)
Mortality rate
Between 11 - 20 %	A2¹⁴, A7¹⁹, A12²⁴, A14²⁶, A18³⁰, A25³⁷	6 (24)
Between 21- 30 %	A1¹³, A4¹⁶, A5¹⁷, A6¹⁸, A9²¹, A13²⁵, A17²⁹, A19³¹, A21³³	9 (36)
Between 31 - 40%	A3¹⁵, A20³², A24³⁶	3 (12)
Between 41% - 50%	A11²³, A22³⁴	2 (8)
Higher than 50%	A10²², A15²⁷	2 (8)

[TFN1] Note: *LILACS: Latin American & Caribbean Literature on Health Sciences; †Scopus: Elsevier’s SCOPUS; ‡MEDLINE: Medical Literature Analysis and Retrieval System Online; §CINAHL: Cumulative Index of Nursing and Allied Health; ||SciELO: Scientific Electronic Library Online; ¶Wiley: Wiley Online Library.